Atrial fibrillation (AF) is an independent risk factor for ischemic stroke occurrence, severity,
recurrence, and mortality. Anticoagulation therapy for the prevention of thromboembolism is …

Венозные тромбоэмболические нарушения часто встречаются в практике врачей
любого профиля. Для профилактики и лечения этих осложнений применяются гепарин …

Introduction: Traditional oral anticoagulants, such as warfarin, are effective but require
frequent laboratory monitoring for dose adjustment and have several known interactions …

Введение. В структуре заболеваемости и смертности сердечно-сосудистые
заболевания во всем мире занимают лидирующее место, среди них весомая часть …

Introduction: Apixaban is a novel oral anticoagulant for the management of thromboembolic
disease. In the present research work, a novel LC-MS/MS method was developed and …

Factor X is one of the main enzymes in blood coagulation cascade. It is present at the middle
point of intrinsic and extrinsic pathways and become activated once an injury occur. Its basic …

The new oral anticoagulants (NOACs) have radically changed the approach to the treatment
and prevention of thromboembolic pulmonary embolism. The authors of this position paper …

A decade ago, oral anticoagulants were limited to Vitamin K antagonists, ie, warfarin. Since
2010, the US Food and Drug Administration has approved several non-Vitamin K oral …

The new oral anticoagulants (NOACs) have radically changed the approach to the treatment
and prevention of thromboembolic pulmonary embolism. The authors of this position paper …

Introduktion De första nya orala antikoagulantia (NOAC) preparaten-eller DOAC (Direct oral
anticoagulants) som de kallas nu-kom år 2008. Åtta år senare är warfarin fortfarande den …